Inscripta
Inscripta Oy is a Finnish language-technology company that develops a proprietary, AI-powered speech recognition solution for healthcare and social care professionals. Its standalone Inscripta Direct app provides real-time medical dictation that works with any microphone and any EHR without integration, saving clinicians around 45 minutes of documentation time daily. The company serves leading Finnish healthcare providers and reports 96-98% transcription accuracy.
Acquired
Inscripta has been acquired
This company is no longer available on our private secondary market.
Overview
Company data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Founded
2015
Employees
11–50
Total Funding
$1M
6 rounds
Latest Valuation
$0.9B
March 2021
Funding
Total raised $1M across 6 rounds
Funding data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Last updated 06-19-2026
Latest Round
Type
Series E
Date
March 2021
Amount
$150M
Valuation
—
Lead Investors
| Date | Round | Amount Raised | Valuation | Lead Investors |
|---|---|---|---|---|
| March 2021 | Series E | $150M | — | Fidelity Management & Research, D1 Capital Partners, T. Rowe Price |
| December 2019 | Series D | $125M | — | Oak HC/FT |
| December 2018 | Series C Extension | $50M | — | Existing investors |
Leadership
Simo Sorsakivi
Co-Founder
Joni Aaltonen
Co-Founder
Peter Smit
Co-Founder
Competitors
Competitor list is illustrative and may be incomplete, stale, or erroneous.
Ginkgo Bioworks
Public synthetic biology platform offering cell programming and biomanufacturing services for microbial strain engineering.
Zymergen
Synthetic biology / industrial bio strain engineering company (acquired by Ginkgo Bioworks in 2022).
Twist Bioscience
Synthetic DNA manufacturer providing oligo pools and genes used in genome engineering workflows.
Synthego
Full-stack CRISPR genome engineering platform offering synthetic guide RNAs, edited cell lines, and discovery services.
Caribou Biosciences
Public CRISPR-based genome-editing company focused on allogeneic cell therapies.
Manus Bio
Industrial biotech / cell factory engineering company; merged with Inscripta in April 2025 - formerly a peer in microbial bioproduction.
Access live market data
Sign UpData collected with AI, which can make mistakes. Please double-check this information.